AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1798376 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergometer rowing
Number of subjects: 10
Study 1798376 — intervention group
Group type: COMPARATOR
Intervention: Arm cranking
Number of subjects: 10
Study 1798376 — intervention group
Group type: EXPERIMENTAL
Intervention: Capillary blood lactate
Number of subjects: 10
Study 1798376 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial bicarbonate
Number of subjects: 10
Study 1798376 — intervention group
Group type: EXPERIMENTAL
Intervention: pH levels
Number of subjects: 10
Study 7045754 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin (2-dose course)
Number of subjects: 91
Study 7045754 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 31241541 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate ART
Number of subjects: 1134
Study 31241541 — intervention group
Group type: COMPARATOR
Intervention: Deferred ART
Number of subjects: 1134
Study 27636836 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmental traction therapy along with conventional physiotherapy, 15 sessions, 5 times a week for 3 weeks.
Number of subjects: 15
Study 25935214 — intervention group
Group type: EXPERIMENTAL
Intervention: Social network peer education intervention
Number of subjects: 0
Study 25935214 — intervention group
Group type: COMPARATOR
Intervention: Control arm participants
Number of subjects: 0
Study 23172404 — intervention group
Group type: EXPERIMENTAL
Intervention: High skilled hand (HS) to low skilled hand (LS) transfer
Number of subjects: 80
Study 23172404 — intervention group
Group type: EXPERIMENTAL
Intervention: Low skilled hand (LS) to high skilled hand (HS) transfer
Number of subjects: 80
Study 23172404 — intervention group
Group type: COMPARATOR
Intervention: Residual pinch force
Number of subjects: 80
Study 23172404 — intervention group
Group type: COMPARATOR
Intervention: Upper limb motricity (Motricity Index)
Number of subjects: 80
Study 23172404 — intervention group
Group type: COMPARATOR
Intervention: Side of hemiparesis
Number of subjects: 80
Study 23172404 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategy adopted in the first trial
Number of subjects: 80
Study 21878941 — intervention group
Group type: EXPERIMENTAL
Intervention: cediranib 20 mg per day plus carboplatin and paclitaxel
Number of subjects: 60
Study 21878941 — intervention group
Group type: COMPARATOR
Intervention: placebo plus carboplatin and paclitaxel
Number of subjects: 60
Study 21878941 — intervention group
Group type: EXPERIMENTAL
Intervention: cediranib 20 mg per day followed by cediranib (concurrent plus maintenance)
Number of subjects: 60
Study 19643440 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone (Ox)
Number of subjects: 44
Study 19643440 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pl)
Number of subjects: 44
Study 17847641 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate air polishing (Prophypearls)
Number of subjects: 0
Study 17847641 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycine air polishing (ClinPro Prophypowder)
Number of subjects: 0
Study 17847641 — intervention group
Group type: COMPARATOR
Intervention: Control groups (no air polishing)
Number of subjects: 0
Study 15455650 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean‐type diet (MD)
Number of subjects: 42
Study 15455650 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine supplementation (240 ml/day) with MD
Number of subjects: 42
Study 15455650 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine supplementation (240 ml/day) with HFD
Number of subjects: 42
Study 15455650 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine supplementation
Number of subjects: 42
Study 15455650 — intervention group
Group type: COMPARATOR
Intervention: High‐fat diet (HFD)
Number of subjects: 42
Study 11432629 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy (MMM chemotherapy for ER-negative patients: methotrexate 30 mg/m2, mitozantrone 7 mg/m2, mitomycin 7 mg/m2 every three weeks for three months; Goserelin 3.75 mg monthly for premenopausal ER-positive patients; Formestane 250 mg every two weeks for postmenopausal ER-positive patients)
Number of subjects: 210
Study 11432629 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy
Number of subjects: 210
Study 9800062 — intervention group
Group type: EXPERIMENTAL
Intervention: Naphcon‐A with lenses in place
Number of subjects: 23
Study 9800062 — intervention group
Group type: COMPARATOR
Intervention: Naphcon‐A with lenses removed for 5 minutes
Number of subjects: 23
Study 7829594 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratories' own procedures
Number of subjects: 9
Study 7829594 — intervention group
Group type: EXPERIMENTAL
Intervention: Consensus procedure established from best results of first panel
Number of subjects: 9
Study 7829594 — intervention group
Group type: EXPERIMENTAL
Intervention: Third panel with three positive samples and four successive dilutions
Number of subjects: 9
Study 3139776 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminum hydroxide-adsorbed vaccine (25 micrograms protein and polysaccharide administered intramuscularly)
Number of subjects: 0
Study 3139776 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl (control group for comparison)
Number of subjects: 0
Study 30509509 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg Q4W
Number of subjects: 0
Study 30509509 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg Q2W
Number of subjects: 0
Study 30509509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28240685 — intervention group
Group type: EXPERIMENTAL
Intervention: Men with primary hypertension
Number of subjects: 209
Study 28240685 — intervention group
Group type: COMPARATOR
Intervention: Women with primary hypertension
Number of subjects: 209
Study 28240685 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 209
Study 28240685 — intervention group
Group type: EXPERIMENTAL
Intervention: Low cardiorespiratory fitness (CRF) group
Number of subjects: 209
Study 25928792 — intervention group
Group type: EXPERIMENTAL
Intervention: Audit and feedback intervention
Number of subjects: 0
Study 25928792 — intervention group
Group type: COMPARATOR
Intervention: Education (control)
Number of subjects: 0
Study 23596980 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-based intervention
Number of subjects: 477
Study 23596980 — intervention group
Group type: EXPERIMENTAL
Intervention: Islamic-based intervention
Number of subjects: 477
Study 23596980 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined program
Number of subjects: 477
Study 23596980 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 477
Study 21192125 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone treatment (Depotrex; Biotek, Inc.)
Number of subjects: 34
Study 19876678 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-week 10-Hz high frequency rTMS add on to antipsychotic therapy, 15 sessions per 3 weeks, 1,000 stimuli per session, stimulation intensity 110% of the individual motor threshold
Number of subjects: 126
Study 19876678 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 126
Study 19876678 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-week 10-Hz high frequency rTMS add on to antipsychotic therapy
Number of subjects: 126
Study 17023843 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% volume of end-tidal sevoflurane concentration maintained for at least 10 minutes
Number of subjects: 30
Study 17023843 — intervention group
Group type: EXPERIMENTAL
Intervention: End-tidal sevoflurane concentration tested at 1.0% to 0.1% volume with an interval of 0.05% volume
Number of subjects: 30
Study 12689403 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated irrigation/suction system
Number of subjects: 47
Study 12689403 — intervention group
Group type: COMPARATOR
Intervention: Standard pressurized technique
Number of subjects: 47
Study 10968301 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-paced exercise
Number of subjects: 155
Study 10968301 — intervention group
Group type: COMPARATOR
Intervention: Class-based exercise
Number of subjects: 155
Study 10968301 — intervention group
Group type: EXPERIMENTAL
Intervention: Dropout (D0)
Number of subjects: 155
Study 10968301 — intervention group
Group type: EXPERIMENTAL
Intervention: Dropout (D3)
Number of subjects: 155
Study 8968172 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 20
Study 8968172 — intervention group
Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 20
Study 1635654 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of lidocaine (xylocaine spray)
Number of subjects: 35
Study 1635654 — intervention group
Group type: COMPARATOR
Intervention: Control group (no lidocaine)
Number of subjects: 35
Study 6366248 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium-containing Collins' 2 solution
Number of subjects: 5
Study 6366248 — intervention group
Group type: COMPARATOR
Intervention: Magnesium-free Euro-Collins' solution
Number of subjects: 5
Study 31436186 — intervention group
Group type: EXPERIMENTAL
Intervention: 360-degree rotation of IOL after placement in the capsular bag
Number of subjects: 50
Study 31436186 — intervention group
Group type: COMPARATOR
Intervention: No rotation of IOL (control group)
Number of subjects: 50
Study 29246745 — intervention group
Group type: EXPERIMENTAL
Intervention: LSE liposomal gel
Number of subjects: 0
Study 25753429 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradiscal methylene blue injection
Number of subjects: 15
Study 25550680 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.5 μg.kg(‐1))
Number of subjects: 140
Study 25550680 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (0.025 μg.kg(‐1))
Number of subjects: 140
Study 22841252 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic scalpel for transection of short hepatic veins
Number of subjects: 16
Study 22841252 — intervention group
Group type: COMPARATOR
Intervention: Conventional ligation for transection of short hepatic veins
Number of subjects: 16
Study 22841252 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic scalpel for transection of small hepatic veins (≤ 2 mm)
Number of subjects: 16
Study 22841252 — intervention group
Group type: EXPERIMENTAL
Intervention: Total and per vessel procedure time
Number of subjects: 16
Study 20529754 — intervention group
Group type: EXPERIMENTAL
Intervention: 1/MaxSens (robustness measure)
Number of subjects: 30
Study 20529754 — intervention group
Group type: EXPERIMENTAL
Intervention: Center of pressure measures of postural sway
Number of subjects: 30
Study 20529754 — intervention group
Group type: COMPARATOR
Intervention: Gain and phase margins
Number of subjects: 30
Study 18507654 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone 30 mg daily
Number of subjects: 6
Study 18507654 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone 60 mg daily
Number of subjects: 6
Study 16162759 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural anesthesia followed by postoperative epidural analgesia (TEA) with bupivacaine
Number of subjects: 50
Study 16162759 — intervention group
Group type: COMPARATOR
Intervention: Conventional IV anesthesia (CON)
Number of subjects: 50
Study 16162759 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (TEA and CON)
Number of subjects: 50
Study 14596960 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised confidentiality agreement (conditional confidentiality)
Number of subjects: 444
Study 14596960 — intervention group
Group type: COMPARATOR
Intervention: Original consent form and protocol (unconditional confidentiality)
Number of subjects: 444
Study 9558183 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID treatment
Number of subjects: 8
Study 9558183 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 8
Study 8980009 — intervention group
Group type: EXPERIMENTAL
Intervention: CAG trinucleotide repeat expansion detected using the repeat expansion detection (RED) method
Number of subjects: 2
Study 8980009 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 2
Study 2370924 — intervention group
Group type: EXPERIMENTAL
Intervention: High-osmolality contrast media
Number of subjects: 30
Study 2370924 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blocker (nifedipine)
Number of subjects: 30
Study 2370924 — intervention group
Group type: COMPARATOR
Intervention: Low-osmolality contrast media
Number of subjects: 30
Study 363104 — intervention group
Group type: EXPERIMENTAL
Intervention: N-n-propyl norapomorphine (NPA) with suboptimal doses of levodopa
Number of subjects: 12
Study 363104 — intervention group
Group type: EXPERIMENTAL
Intervention: N-n-propyl norapomorphine (NPA) with levodopa plus carbidopa (Sinemet)
Number of subjects: 12
Study 363104 — intervention group
Group type: EXPERIMENTAL
Intervention: N-n-propyl norapomorphine (NPA)
Number of subjects: 12
Study 30740632 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal diversion device (FDD)
Number of subjects: 54
Study 30740632 — intervention group
Group type: COMPARATOR
Intervention: Ileostomy (stoma)
Number of subjects: 54
Study 28236309 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual supervision of home-visiting professionals
Number of subjects: 0
Study 28236309 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical supervision
Number of subjects: 0
Study 26147387 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehypertension (preHTN)
Number of subjects: 7802
Study 23683600 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of teriparatide (20 μg daily) and denosumab (60 mg every 6 months)
Number of subjects: 100
Study 23683600 — intervention group
Group type: COMPARATOR
Intervention: Teriparatide (20 μg daily)
Number of subjects: 100
Study 23683600 — intervention group
Group type: COMPARATOR
Intervention: Denosumab (60 mg every 6 months)
Number of subjects: 100
Study 23683600 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of teriparatide and denosumab
Number of subjects: 100
Study 22024489 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean-style low-glycemic-load diet for 12 weeks
Number of subjects: 25
Study 18300863 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 48
Study 18300863 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 16284226 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary arterial hypertension patients
Number of subjects: 46
Study 12672281 — intervention group
Group type: EXPERIMENTAL
Intervention: RMP-7 and carboplatin
Number of subjects: 122
Study 12672281 — intervention group
Group type: COMPARATOR
Intervention: Placebo and carboplatin
Number of subjects: 122
Study 11529325 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice test applied on the eyelids for 2 minutes
Number of subjects: 40
Study 9751675 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG (Coronary Artery Bypass Grafting)
Number of subjects: 1829
Study 9751675 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCA (Percutaneous Transluminal Coronary Angioplasty)
Number of subjects: 1829
Study 9751675 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 1829
Study 9751675 — intervention group
Group type: COMPARATOR
Intervention: PTCA
Number of subjects: 1829
Study 9751675 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG and PTCA
Number of subjects: 1829
Study 8064552 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical liposome system bearing local anaesthetic lignocaine
Number of subjects: 0
Study 8064552 — intervention group
Group type: COMPARATOR
Intervention: Conventional topical application
Number of subjects: 0
Study 3287894 — intervention group
Group type: EXPERIMENTAL
Intervention: Undereating (4.2 MJ [1000 kcal] for 4 d)
Number of subjects: 12
Study 3287894 — intervention group
Group type: EXPERIMENTAL
Intervention: Overeating (12.6 MJ [3000 kcal] for 2 d)
Number of subjects: 12
Study 3287894 — intervention group
Group type: COMPARATOR
Intervention: Control (Undereating)
Number of subjects: 12
Study 8272252 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysers containing cuprammonium cellulose (G10‐3N and G120 M)
Number of subjects: 7
Study 8272252 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysers containing cuprammonium cellulose
Number of subjects: 7
Study 8272252 — intervention group
Group type: EXPERIMENTAL
Intervention: PAN copolymer‐ and PMMA‐containing dialysers (Filtral and T 150)
Number of subjects: 7
Study 8272252 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysers containing cellulose acetate and polysulphone membranes (Duo‐Flux Artificial Kidney, CD 4000, and F 60)
Number of subjects: 7
Study 118360 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyldigoxin (0.4 mg/day)
Number of subjects: 80
Study 118360 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyldigoxin (0.4 mg/day) + Hydergin (3 mg/day)
Number of subjects: 80
Study 31238507 — intervention group
Group type: EXPERIMENTAL
Intervention: 60-g faecal microbiota transplantation (FMT)
Number of subjects: 10
Study 30982023 — intervention group
Group type: EXPERIMENTAL
Intervention: Food-specific IgG4
Number of subjects: 46
Study 30982023 — intervention group
Group type: EXPERIMENTAL
Intervention: Total IgE
Number of subjects: 46
Study 30982023 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific IgE
Number of subjects: 46
Study 27986738 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored health messages (THM)
Number of subjects: 357
Study 27986738 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback to oncologists about the patients' trial THM
Number of subjects: 357
Study 27986738 — intervention group
Group type: COMPARATOR
Intervention: No feedback to oncologists about the patients' trial THM
Number of subjects: 357
Study 24718886 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab 6.0 mg/kg every 2 weeks + FOLFOX4
Number of subjects: 1183
Study 24718886 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX4
Number of subjects: 1183
Study 22431413 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 9355
Study 19436060 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding clinic intervention within 1 week postpartum
Number of subjects: 522
Study 19436060 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 522
Study 19436060 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding clinic intervention
Number of subjects: 522
Study 17264105 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength and functional exercises
Number of subjects: 32
Study 17264105 — intervention group
Group type: COMPARATOR
Intervention: Strength training
Number of subjects: 32
Study 15339468 — intervention group
Group type: EXPERIMENTAL
Intervention: Sansheng Huatan Decoction combined with chemotherapy
Number of subjects: 160
Study 15339468 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy only (Control)
Number of subjects: 160
Study 12700441 — intervention group
Group type: EXPERIMENTAL
Intervention: sultamicillin (2 x 375 mg orally)
Number of subjects: 108
Study 12700441 — intervention group
Group type: COMPARATOR
Intervention: amoxicillin (3 x 500 mg orally)
Number of subjects: 108
Study 12700441 — intervention group
Group type: EXPERIMENTAL
Intervention: sultamicillin
Number of subjects: 108
Study 12700441 — intervention group
Group type: COMPARATOR
Intervention: amoxicillin
Number of subjects: 108
Study 9627822 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety management training (AMT)
Number of subjects: 6
Study 9627822 — intervention group
Group type: COMPARATOR
Intervention: Implosive therapy (IT)
Number of subjects: 6
Study 8088611 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal chemotherapy (ip): cisplatin 200 mg/m2 plus etoposide 350 mg/m2 every 4 weeks for six cycles.
Number of subjects: 62
Study 8088611 — intervention group
Group type: COMPARATOR
Intervention: Intravenous chemotherapy (iv): cisplatin 100 mg/m2 plus cyclophosphamide 600 mg/m2 every 3 weeks for six cycles.
Number of subjects: 62
Study 8088611 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal chemotherapy (ip)
Number of subjects: 62
Study 8088611 — intervention group
Group type: COMPARATOR
Intervention: Intravenous chemotherapy (iv)
Number of subjects: 62
Study 8088611 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 62
Study 2779810 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 1 mg/h
Number of subjects: 20
Study 2779810 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 0.03 mg/h
Number of subjects: 20
Study 1108581 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.3 mg/kg of 0.5% plain bupivacaine
Number of subjects: 11
Study 1108581 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.6 mg/kg of 1.0% plain etidocaine
Number of subjects: 11
Study 1108581 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 11
Study 31207663 — intervention group
Group type: COMPARATOR
Intervention: Red meat (control group)
Number of subjects: 75
Study 31207663 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy bean
Number of subjects: 75
Study 31207663 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-soy legume
Number of subjects: 75
Study 31094246 — intervention group
Group type: EXPERIMENTAL
Intervention: Loaded Plyometric Jump Training (LPJT)
Number of subjects: 29
Study 31094246 — intervention group
Group type: COMPARATOR
Intervention: Unloaded Plyometric Jump Training (UPJT)
Number of subjects: 29
Study 31094246 — intervention group
Group type: COMPARATOR
Intervention: Between-group analysis favoring LPJT
Number of subjects: 29
Study 31373837 — intervention group
Group type: EXPERIMENTAL
Intervention: OTX-101 0.09%
Number of subjects: 1048
Study 31373837 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 1048
Study 27848196 — intervention group
Group type: EXPERIMENTAL
Intervention: LT4 oral liquid formulation (SOL)
Number of subjects: 47
Study 27848196 — intervention group
Group type: COMPARATOR
Intervention: LT4 tablet formulation (TAB)
Number of subjects: 47
Study 27848196 — intervention group
Group type: COMPARATOR
Intervention: LT4 formulations (TAB and SOL)
Number of subjects: 47
Study 26143310 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentax Airway Scope AWS‐S200 video laryngoscope (AWS)
Number of subjects: 54
Study 23313701 — intervention group
Group type: EXPERIMENTAL
Intervention: 80mg caffeine
Number of subjects: 19
Study 23313701 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000mg taurine
Number of subjects: 19
Study 23313701 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine and taurine combined
Number of subjects: 19